REMM LIFEPAR Stock Bombay S.E.

REMLIFE

INE549S01028

Pharmaceuticals

Market Closed - Bombay S.E. 06:27:28 2026-10-08 EDT			5-day change	1st Jan Change
0.2500 ^INR	0.00%		-3.85%	-66.67%

02-14	Supha Pharmachem Limited Announces Demise of Kapil Goplani, Company Secretary and Compliance Officer	CI
12-15	Remedium Lifecare Secures Regulatory Approval for Name Change	MT

Supha Pharmachem Limited, formerly Remedium Lifecare Limited, is an India-based pharmaceutical and specialty chemicals company engaged in trading and distribution of raw materials for the pharmaceutical industry. The Company is engaged in the business of trading in advanced pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and other pharma products used viz. Isopropyl Alcohol (IPA) ,Cyclohexane, Diisopropyl Amine (DIPA), Ethyl Acetate, Hydrazine Hydrate, Methylene Dichloride, Potassium Carbonate Powder, Sodium Bicarbonate, Potassium Hydroxide Flakes, Sodium Chloride (common salt), Sodium Carbonate (soda ash), Amino isophthalic Acid, Tellurium(IV) Oxide, Grignard Reagent, Iodine, Selenium Metal Powder, and Trimethyl Sulfoxonium Iodide (TMSI).

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-08	₹0.2500	0.00%	1,522,281
26-10-07	₹0.2500	-3.85%	1,807,886
26-10-06	₹0.2600	+4.00%	1,303,617
26-10-05	₹0.2500	-3.85%	1,112,106
26-10-01	₹0.2600	-3.70%	871,639

Delayed Quote Bombay S.E.

More quotes

As early as today, start finding the best investment opportunities!

Market Cap	137M 1.42M 1.27M 1.18M 1.07M 2.02M 2.04M 14.2M 5.55M 69.72M 5.32M 5.21M 224M	P/E 2024	33.4x	P/E 2025	36.4x
Enterprise Value	11.54B 119M 107M 99.42M 90.3M 170M 171M 1.19B 467M 5.87B 448M 438M 18.86B	EV / Sales 2024	0.28x	EV / Sales 2025	2.99x
Free-Float	79.86%	Yield 2024 *	-	Yield 2025	-

02-14	Supha Pharmachem Limited Announces Demise of Kapil Goplani, Company Secretary and Compliance Officer	CI
12-15	Remedium Lifecare Secures Regulatory Approval for Name Change	MT
12-15	Remedium Lifecare Limited has Changed its Name to Supha Pharmachem Limited	CI
11-14	Supha Pharmachem Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
11-10	Remedium Lifecare Ltd. Announces Board Appointments	CI
25-10-31	Remedium Lifecare Limited Reconstitutes Its Committees	CI
25-10-29	Remedium Lifecare Limited Accepts the Resignation Mansoor Abdul Vahab, Non-Executive- Independent Director, Effective October 29, 2025	CI
25-10-06	Remedium Lifecare Limited Announces Resignation of Dipesh Vinod Vaidya as Non-Executive- Independent Director with Effect from October 6, 2025	CI
25-09-22	Remedium Lifecare approves fundraising not exceeding 1 billion rupees proposed	RE
25-08-25	Remedium Lifecare global export expansion	RE
25-08-25	Remedium Lifecare Ltd. Unveils A Strategic Road Road with Strategic Focus on 4-Point Strategy	CI
25-08-04	Remedium Lifecare Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-05-30	Remedium Lifecare Limited Appoints Kapil Goplani as Company Secretary Cum Compliance Officer	CI

1 week	-3.85%
Current month	-7.41%
1 month	-7.41%
3 months	-24.24%
6 months	-30.56%
Current year	-66.67%

1 week	0.24	0.27
1 month	0.24	0.27
3 years	0.24	26.7
5 years	0.24	31.35
10 years	0.06	31.35

Manager	Title	Age	Since
Ashish Dinanath Parkar DFI	Director of Finance/CFO	-	2019-05-29
Vikas Sadvilkar CTO	Chief Tech/Sci/R&D Officer	-	-

REMM LIFEPAR Stock Bombay S.E.

Stocks

REMLIFE

INE549S01028

Pharmaceuticals

Valuation: REMM LIFEPAR

Chart: REMM LIFEPAR

Latest news: REMM LIFEPAR

Quotes and Performance

Price Extremes

Managers and Directors: REMM LIFEPAR

Other Pharmaceuticals

Financials

Company Profile

Quotes

Director	Title	Age	Since
Adarsh Deepak Munjal BRD	Director/Board Member	38	2023-09-04
Shamim Adil Michal BRD	Director/Board Member	-	2025-01-21
Bikram Mund BRD	Director/Board Member	-	2025-05-29

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REMM LIFEPAR	0.00%	-3.85%	-83.44%	-98.83%	1.04M
ELI LILLY AND COMPANY	+2.70%	+2.73%	+40.91%	+110.31%	1,060B
JOHNSON & JOHNSON	+1.44%	-2.38%	+36.83%	+63.95%	623B
ABBVIE INC.	+1.75%	+3.73%	+16.55%	+83.05%	480B
MERCK & CO., INC.	+0.60%	-1.73%	+62.98%	+37.46%	352B
ROCHE HOLDING AG	-0.94%	+1.81%	+21.97%	+41.64%	345B
NOVARTIS AG	-0.62%	+0.90%	+11.85%	+35.16%	274B
ASTRAZENECA PLC	-0.62%	-1.56%	-5.41%	+11.35%	249B
AMGEN INC.	+2.60%	-2.00%	+39.77%	+54.44%	223B
GILEAD SCIENCES, INC.	+1.82%	-1.48%	+25.75%	+96.48%	182B
Average	-0.38%	-0.48%	+16.77%	+43.50%	420.89B
Weighted average by Cap.	-0.24%	+0.04%	+31.53%	+70.30%

	2024	2025
Net sales	40.42B 418M 373M 348M 316M 596M 600M 4.19B 1.64B 20.56B 1.57B 1.53B 66.08B	4.05B 41.89M 37.43M 34.92M 31.72M 59.74M 60.19M 420M 164M 2.06B 157M 154M 6.63B
Net income	327M 3.38M 3.02M 2.82M 2.56M 4.83M 4.86M 33.89M 13.24M 166M 12.7M 12.43M 535M	21.29M 220K 197K 183K 167K 314K 316K 2.21M 861K 10.83M 826K 809K 34.81M
Net Debt	562M 5.81M 5.19M 4.84M 4.4M 8.28M 8.34M 58.18M 22.73M 286M 21.8M 21.33M 918M	11.4B 118M 105M 98.24M 89.23M 168M 169M 1.18B 461M 5.8B 442M 433M 18.64B